ArticleFrontiers in allergy2026
The Spanish REAL project: expert allergist guidance on allergen immunotherapy based on mixtures from different allergenic sources.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and Effectiveness of Subcutaneous Immunotherapy with an Undiluted Glutaraldehyde-Polymerized Pollen Extract Mixture in Adults and Children with Allergic Rhinitis with or Without Asthma Due to Olive and Grass Pollen.Diseases (Basel, Switzerland) · 2026Article
- Real-World Effectiveness and Safety of Allergen Immunotherapy with a Combination of Glutaraldehyde-Polymerized Allergen Extracts ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increase in polyallergy highlights allergen-specific immunotherapy (AIT) as a crucial therapeutic option for these patients. It is the only etiological treatment capable of modifying the natural course of allergic diseases. Its use, particularly with mixtures from different allergenic sources, varies across regions. In Spain, geographic and environmental diversity leads to complex, heterogeneous sensitization patterns not fully addressed by international guidelines, reinforcing the need for context-specific recommendations integrating current evidence and real clinical practice. Objective: To establish general recommendations for managing polyallergic patients undergoing AIT with mixtures of different allergenic sources in Spain. Methodology: Eight regional meetings with 61 experts were held across Spain using the Workmat® methodology: evidence-based exercises designed to facilitate discussion and consistent data collection. Results: Experts agreed that polymerized allergen extract mixtures offer several advantages over AIT with simultaneous use of individual allergen extracts, as they allow multiple sensitizations to be treated in a single application, simplifying the treatment without compromising safety or efficacy while also saving time and costs and improving treatment adherence. Furthermore, the use of polymerized allergen extracts has improved efficacy and safety in AIT. It is essential to perform an individualized evaluation, according to the type of extract, the mixture, and the patient's comorbidities. Conclusion: The increasing prevalence of polyallergy has emerged as a growing challenge in routine clinical practice. In this context, AIT using polymerized allergen extract mixtures, at optimal doses, tailored to individual sensitization profiles represent a practical and effective approach for managing polyallergy in the Spanish clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.